Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.

Y. Ishida, Y. Agata, K. Shibahara, T. Honjo, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal. ,vol. 11, pp. 3887- 3895 ,(1992) , 10.1002/J.1460-2075.1992.TB05481.X

Peter Carmeliet, Rakesh K. Jain, Angiogenesis in cancer and other diseases Nature. ,vol. 407, pp. 249- 257 ,(2000) , 10.1038/35025220

S. Kopetz, J. Desai, E. Chan, J. R. Hecht, P. J. O'Dwyer, R. J. Lee, K. B. Nolop, L. Saltz, PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Journal of Clinical Oncology. ,vol. 28, pp. 3534- 3534 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.3534

Josep Tabernero, Heinz-Josef Lenz, Salvatore Siena, Alberto Sobrero, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Takayuki Yoshino, Richard M Goldberg, Daniel J Sargent, Andrea Wagner, Dirk Laurent, Michael Teufel, Michael Jeffers, Axel Grothey, Eric Van Cutsem, None, Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial The Lancet Oncology. ,vol. 16, pp. 937- 948 ,(2015) , 10.1016/S1470-2045(15)00138-2

Zi-Xu Yuan, Xiao-Yan Wang, Qi-Yuan Qin, De-Feng Chen, Qing-Hua Zhong, Lei Wang, Jian-Ping Wang, The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis PLoS ONE. ,vol. 8, pp. e65995- ,(2013) , 10.1371/JOURNAL.PONE.0065995

Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864

Thomas Powles, Joseph Paul Eder, Gregg D. Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature. ,vol. 515, pp. 558- 562 ,(2014) , 10.1038/NATURE13904

Alena Gros, Paul F. Robbins, Xin Yao, Yong F. Li, Simon Turcotte, Eric Tran, John R. Wunderlich, Arnold Mixon, Shawn Farid, Mark E. Dudley, Ken-ichi Hanada, Jorge R. Almeida, Sam Darko, Daniel C. Douek, James C. Yang, Steven A. Rosenberg, PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors Journal of Clinical Investigation. ,vol. 124, pp. 2246- 2259 ,(2014) , 10.1172/JCI73639

Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn, Enric Carcereny, Myung-Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D Hellmann, Omid Hamid, Jonathan W Goldman, Jean-Charles Soria, Marisa Dolled-Filhart, Ruth Z Rutledge, Jin Zhang, Jared K Lunceford, Reshma Rangwala, Gregory M Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi, None, Pembrolizumab for the treatment of non-small cell lung cancer The New England Journal of Medicine. ,vol. 372, pp. 2018- 2028 ,(2015) , 10.1056/NEJMOA1501824

Filippo Pietrantonio, Fausto Petrelli, Andrea Coinu, Maria Di Bartolomeo, Karen Borgonovo, Claudia Maggi, Mary Cabiddu, Roberto Iacovelli, Ilaria Bossi, Veronica Lonati, Mara Ghilardi, Filippo de Braud, Sandro Barni, Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis European Journal of Cancer. ,vol. 51, pp. 587- 594 ,(2015) , 10.1016/J.EJCA.2015.01.054